Exelixis, Inc.
EXEL
Rang in Aktien
#1384
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Aktienkurs
$64.01
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$16.09B
Veränderung (1 Tag)
2.11%
Veränderung (1 Jahr)
77.15%
Land
US
Handel Exelixis, Inc. (EXEL)
Kategorie
Healthcare
Umsatz von Exelixis, Inc. (EXEL)
Umsatz im Jul 2026 TTM: $2.44B
Laut den aktuellen Finanzberichten von Exelixis, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $2.44B. Im Jahr 2025 erzielte das Unternehmen einen Umsatz von $2.17B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $1.83B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Exelixis, Inc. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $2.44B | 12.32% |
| 2025 | $2.17B | 18.49% |
| 2023 | $1.83B | 13.60% |
| 2022 | $1.61B | 12.27% |
| 2021 | $1.43B | 45.31% |
| 2020 | $987.54M | 2.04% |
| 2019 | $967.78M | 13.35% |
| 2018 | $853.83M | 88.70% |
| 2017 | $452.48M | 136.34% |
| 2016 | $191.45M | 415.05% |
| 2015 | $37.17M | 48.03% |
| 2014 | $25.11M | -19.87% |
| 2013 | $31.34M | -33.96% |
| 2012 | $47.45M | -83.62% |
| 2011 | $289.64M | 56.52% |
| 2010 | $185.05M | 21.93% |
| 2009 | $151.76M | 28.76% |
| 2008 | $117.86M | 3.87% |
| 2007 | $113.47M | 15.00% |
| 2006 | $98.67M | 29.90% |
| 2005 | $75.96M | 43.71% |
| 2004 | $52.86M | 2.56% |
| 2003 | $51.54M | 16.29% |
| 2002 | $44.32M | 8.09% |
| 2001 | $41.01M | 65.62% |
| 2000 | $24.76M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 418.26% |
US
|
|
| $2.23B | -8.54% |
US
|
|
| $15.74B | 546.34% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 147.19% |
NL
|
